The chemotherapy-induced neutropenia causes mortality and morbidity at a significant rate (Aapro et al., 2011; Fontanella et al., 2014). Fever is frequently observed during chemotherapy-induced neutropenia. Neutropenia-related fever could be encountered for at least once in 10-50% of patients with solid tumor and >80% of patients with hematological malignancy (Freifeld et al., 2011). In patient...

STUDY OBJECTIVE To assess the effectiveness, safety, and cost of empiric treatment of febrile neutropenia before and after implementing an algorithm in which voriconazole was substituted for liposomal amphotericin B (L-AmB). DESIGN Retrospective cohort analysis. SETTING An 850-bed tertiary care hospital, which is also a referral site for patients with acute leukemia. PATIENTS Fifty-five a...

BACKGROUND Febrile neutropenia (FN) is generally a complication of cancer chemotherapy. OBJECTIVES We retrospectively evaluated the febrile neutropenia episodes and their outcomes with respect to modification rates of non-carbapenem-based empirical antibacterial therapy and vancomycin-resistant enterococcus (VRE) colonisation that caused to VRE bacteremia in patients with hematological malign...

Objective: We aimed to investigate the effectiveness of quick Sequential Organ Failure Assessment (qSOFA), Multinational Association for Supportive Care in Cancer (MASCC), and Clinical Index Stable Febrile Neutropenia (CISNE) scores identifying low-risk febrile neutropenia patients among with chemotherapy-associated emergency department setting.
 Material Method: The risk were calculated d...

Aim: One method to deal with febrile neutropenia is the use of granulocyte colony stimulating factors (G-CSFs). Pegfilgrastim or Filgrastim injection can lead to a reduction in febrile neutropenia and severe neutropenia in patients receiving chemotherapy. This study aimed to compare the cost-effectiveness of using Pegfilgrastim, 3-day Filgrastim and 1-day Filgrastim medication strategies for th...

BACKGROUND Recent investigations of febrile neutropenia in pediatric cancer patients have identified subsets of low-risk patients who can be managed with less antibiotic therapy than previously recommended standards. METHODS AND MATERIALS PubMed and Medline were searched for prospective trials and reviews of febrile neutropenia in children. Magnitude and duration of fever and neutropenia, com...

INTRODUCTION Rising rates of antibiotic resistance prompted a review of antibiotic use policies hospitalwide. The Department of Haematology established a new set of consensus guidelines in 2002 for antibiotic use in febrile neutropenia. The aim of our study was to audit adherence to the guidelines established for febrile neutropenia in patients treated for haematologic malignancies. MATERIALS...

Children with malignancy receiving chemotherapy are prone to suffer from bacteremia and sepsis, which may consequently lead to significant neutropenia, loss of mucosal integrity, and the need for an indwelling central venous catheter. Bacteremia reportedly occurs more often in neutropenic than non-neutropenic episodes (20% vs. 3%) [1], and the presence of sepsis or bacteremia confers a 10-fold ...